Sonnet Biotherapeutics Holdings Stock Fundamentals
| SONN Stock | USD 2.63 0.14 5.05% |
Sonnet Biotherapeutics Holdings fundamentals help investors to digest information that contributes to Sonnet Biotherapeutics' financial success or failures. It also enables traders to predict the movement of Sonnet Stock. The fundamental analysis module provides a way to measure Sonnet Biotherapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Sonnet Biotherapeutics stock.
At this time, Sonnet Biotherapeutics' Tax Provision is very stable compared to the past year. As of the 29th of November 2024, Interest Income is likely to grow to about 955 K, while Selling General Administrative is likely to drop about 2.4 M. Sonnet | Select Account or Indicator |
Sonnet Biotherapeutics Holdings Company Return On Equity Analysis
Sonnet Biotherapeutics' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Sonnet Biotherapeutics Return On Equity | -2.65 |
Most of Sonnet Biotherapeutics' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Sonnet Biotherapeutics Holdings is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Sonnet Total Stockholder Equity
Total Stockholder Equity |
|
Based on the latest financial disclosure, Sonnet Biotherapeutics Holdings has a Return On Equity of -2.6457. This is 88.96% lower than that of the Biotechnology sector and 92.74% lower than that of the Health Care industry. The return on equity for all United States stocks is notably higher than that of the company.
Sonnet Biotherapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Sonnet Biotherapeutics's current stock value. Our valuation model uses many indicators to compare Sonnet Biotherapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Sonnet Biotherapeutics competition to find correlations between indicators driving Sonnet Biotherapeutics's intrinsic value. More Info.Sonnet Biotherapeutics Holdings is rated fifth in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Sonnet Biotherapeutics' Return On Equity is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Sonnet Biotherapeutics' earnings, one of the primary drivers of an investment's value.Sonnet Biotherapeutics' Earnings Breakdown by Geography
Sonnet Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Sonnet Biotherapeutics' direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Sonnet Biotherapeutics could also be used in its relative valuation, which is a method of valuing Sonnet Biotherapeutics by comparing valuation metrics of similar companies.Sonnet Biotherapeutics is currently under evaluation in return on equity category among its peers.
Sonnet Biotherapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Sonnet Biotherapeutics from analyzing Sonnet Biotherapeutics' financial statements. These drivers represent accounts that assess Sonnet Biotherapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Sonnet Biotherapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 36.3M | 193.5M | 118.9M | 51.0M | 23.8M | 34.4M | |
| Enterprise Value | 46.1M | 186.5M | 91.4M | 48.2M | 21.7M | 43.8M |
Sonnet Biotherapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Sonnet Biotherapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Sonnet Biotherapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Sonnet Fundamentals
| Return On Equity | -2.65 | ||||
| Return On Asset | -0.97 | ||||
| Operating Margin | (219.69) % | ||||
| Current Valuation | (1.2 M) | ||||
| Shares Outstanding | 837.66 K | ||||
| Shares Owned By Insiders | 4.22 % | ||||
| Shares Owned By Institutions | 0.61 % | ||||
| Number Of Shares Shorted | 35.2 K | ||||
| Price To Book | 0.84 X | ||||
| Price To Sales | 39.42 X | ||||
| Revenue | 147.81 K | ||||
| Gross Profit | (21.09 M) | ||||
| EBITDA | (18.72 M) | ||||
| Net Income | (18.83 M) | ||||
| Cash And Equivalents | 5.22 M | ||||
| Cash Per Share | 1.21 X | ||||
| Total Debt | 203.91 K | ||||
| Debt To Equity | 0.36 % | ||||
| Current Ratio | 1.10 X | ||||
| Book Value Per Share | 4.01 X | ||||
| Cash Flow From Operations | (21.34 M) | ||||
| Short Ratio | 0.03 X | ||||
| Earnings Per Share | (0.96) X | ||||
| Target Price | 240.0 | ||||
| Number Of Employees | 12 | ||||
| Beta | 1.05 | ||||
| Market Capitalization | 2.2 M | ||||
| Total Asset | 5.43 M | ||||
| Retained Earnings | (110.24 M) | ||||
| Working Capital | (786.37 K) | ||||
| Net Asset | 5.43 M |
About Sonnet Biotherapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Sonnet Biotherapeutics Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Sonnet Biotherapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Sonnet Biotherapeutics Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 1.2 M | 1.2 M | |
| Total Revenue | 40.6 M | 42.6 M | |
| Cost Of Revenue | 7.9 M | 11.8 M | |
| Stock Based Compensation To Revenue | 1.51 | 1.41 | |
| Sales General And Administrative To Revenue | 0.01 | 0.01 | |
| Capex To Revenue | 0.06 | 0.05 | |
| Revenue Per Share | 69.9 K | 91.8 K | |
| Ebit Per Revenue | (0.10) | (0.10) |
Check out Sonnet Biotherapeutics Piotroski F Score and Sonnet Biotherapeutics Altman Z Score analysis. You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sonnet Biotherapeutics. If investors know Sonnet will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sonnet Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.96) | Revenue Per Share 0.019 | Quarterly Revenue Growth (0.50) | Return On Assets (0.97) | Return On Equity (2.65) |
The market value of Sonnet Biotherapeutics is measured differently than its book value, which is the value of Sonnet that is recorded on the company's balance sheet. Investors also form their own opinion of Sonnet Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Sonnet Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sonnet Biotherapeutics' market value can be influenced by many factors that don't directly affect Sonnet Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sonnet Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sonnet Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sonnet Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.